ICUI Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -2.56% compared to ICU Medical's net margin of 14.45%. ICU Medical's return on equity of -4.64% beat Boston Scientific's return on equity of 9.57%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 39.75%. On the other hand Boston Scientific has an analysts' consensus of $117.05 which suggests that it could grow by 15.06%. Given that ICU Medical has higher upside potential than Boston Scientific, analysts believe ICU Medical is more attractive than Boston Scientific.

ICU Medical has a beta of 0.881, which suggesting that the stock is 11.918% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are smaller than Boston Scientific quarterly revenues of $4.7B. ICU Medical's net income of -$15.5M is lower than Boston Scientific's net income of $674M. Notably, ICU Medical's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 74.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.35x versus 8.63x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Enovis has a net margin of -2.56% compared to ICU Medical's net margin of -10.02%. ICU Medical's return on equity of -4.64% beat Enovis's return on equity of -26.77%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 39.75%. On the other hand Enovis has an analysts' consensus of $56.50 which suggests that it could grow by 82.97%. Given that Enovis has higher upside potential than ICU Medical, analysts believe Enovis is more attractive than ICU Medical.

ICU Medical has a beta of 0.881, which suggesting that the stock is 11.918% less volatile than S&P 500. In comparison Enovis has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.773%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Enovis quarterly revenues of $558.8M. ICU Medical's net income of -$15.5M is higher than Enovis's net income of -$56M. Notably, ICU Medical's price-to-earnings ratio is -- while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.35x versus 0.80x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -2.56% compared to ICU Medical's net margin of -45.89%. ICU Medical's return on equity of -4.64% beat Masimo's return on equity of -39.91%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 39.75%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 12.02%. Given that ICU Medical has higher upside potential than Masimo, analysts believe ICU Medical is more attractive than Masimo.

ICU Medical has a beta of 0.881, which suggesting that the stock is 11.918% less volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.725%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Masimo quarterly revenues of $372M. ICU Medical's net income of -$15.5M is higher than Masimo's net income of -$170.7M. Notably, ICU Medical's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.35x versus 4.47x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -2.56% compared to ICU Medical's net margin of 8.48%. ICU Medical's return on equity of -4.64% beat Merit Medical Systems's return on equity of 9.19%.

ICU Medical has a consensus price target of $186.20, signalling upside risk potential of 39.75%. On the other hand Merit Medical Systems has an analysts' consensus of $108.55 which suggests that it could grow by 15.76%. Given that ICU Medical has higher upside potential than Merit Medical Systems, analysts believe ICU Medical is more attractive than Merit Medical Systems.

ICU Medical has a beta of 0.881, which suggesting that the stock is 11.918% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.793%.

ICU Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

ICU Medical quarterly revenues are $604.7M, which are larger than Merit Medical Systems quarterly revenues of $355.4M. ICU Medical's net income of -$15.5M is lower than Merit Medical Systems's net income of $30.1M. Notably, ICU Medical's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 45.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical is 1.35x versus 4.06x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.